Secoxyloganin inhibits growth of breast cancer MDA-MB-231 cells via induction of apoptosis and cell cycle arrest

Jie Ma,Cong Peng
DOI: https://doi.org/10.1080/26895293.2024.2408433
IF: 1.044
2024-10-05
All Life
Abstract:This study was set to study the anti-proliferative effects of secoxyloganin in MDA-MB-231 breast cancer cells. The MTT cell viability assay results demonstrated that secoxyloganin significantly ( p < 0.05) inhibited the growth of the MDA-MB-231 cells with an IC 50 of 6.5 μM which was significantly ( p < 0.05) lower than the IC 50 of 38 μM against the normal fR2 cells. Unveiling of molecular mechanism revealed that secoxyloganin disrupted the DNA integrity of MDA-MB-231 cells and triggered apoptosis. Annexin V/PI staining revealed that the percentage of apoptotic MDA-MB-231 cells increased from 3.7% in control to 40.2% at 24 μM of secoxyloganin. This was accompanied by an enhancement of Bax, and suppression of Bcl-2. The effects of secoxyloganin on the distribution of cells in various cell cycle phases was also assessed. The results showed the proportion of cells in the G 0 /G 1 phase increased from 32.76% in control to 77.50% at 24 μM of secoxyloganin suggesting G 0 /G 1 cell cycle arrest. This was also associated with suppression of cyclin D2 expression. Taken together, these findings demonstrate the anticancer properties of secoxyloganin through cell cycle arrest and apoptosis.
multidisciplinary sciences
What problem does this paper attempt to address?